"MRD is actually telling us there’s a residual ember." – Dr Doug Flora In this video, learn how oncologists can act early to extinguish that ember of cancer before the fire starts again. 🩺 Insights from Dr Flora & Dr Patt: hubs.la/Q03hjj5F0 #CancerDiagnostics

From surgery to recurrence surveillance, Haystack MRD™ tracks ctDNA across the entire treatment management journey—empowering oncologists to make informed, timely treatment decisions. Learn more at hubs.la/Q03bc9n30 #CancerCare #OncologyTesting

Got questions about MRD testing or ctDNA technology? We’ve got answers. Meet the Haystack MRD team at booth 104 during the 2025 Community Oncology Conference and explore how ultrasensitive MRD testing can support your practice. #COA2025 #OncologyExperts #MRD #PrecisionOncology

Watch 2 leading oncologists take a deep dive into how groundbreaking advancements are providing a “clearer crystal ball” for guiding patient care. 🎥 Watch the full video at hubs.la/Q03g8fqJ0 #CancerDiagnostics #MRDTesting ##OncologyLeadership

Visiting #COA2025 in Orlando? Don’t miss us at booth 104! With the ability to detect 95% of MRD cases at 0.0006% tumor fraction, Haystack MRD delivers insights powered by precision so clinicians can detect residual disease with confidence. Come by and say hello—we’d love to chat.

Why does ctDNA matter? It reveals what imaging can’t. Haystack MRD™ uses ctDNA to detect residual disease that may otherwise go undetected. Learn more at hubs.la/Q038gn4F0 #CancerDetection #HaystackMRD

Haystack MRD™ is more than a test—we’re a partner in progress. Visit us at booth 11069 during #ASCO25 to join the conversation around MRD, precision oncology, and how we can support your practice and patients. Let’s connect in Chicago! #OncologyCommunity #CancerDetection

The future of cancer recurrence monitoring is here. Haystack MRD™ enables real-time assessment of therapy effectiveness through ctDNA kinetics. Learn more at hubs.la/Q038gPN50 #OncologyInnovation #MRDTesting

At #ASCO25, Haystack MRD invites you to booth 11069 to discuss how we can detect and manage residual disease—together. Whether you’re a clinician, researcher, or care partner, we want to hear from you. Let’s talk about what’s next in MRD. Learn more: hubs.la/Q03lhVwN0

Confident treatment choices require sensitive tools. Haystack MRD™ is designed to detect even the smallest traces of ctDNA in a blood sample, for earlier insights. Learn more at hubs.la/Q038gs450 #MRDTesting #CancerCare

A new poll reveals oncologists’ perspectives on using ctDNA-based MRD testing to monitor cancer recurrence. Discover the insights and see how MRD testing can help improve patient outcomes: hubs.ly/Q03nChFv0

What are the biggest barriers to recurrence monitoring in cancer care? Find out what oncologists had to say in our latest poll. hubs.la/Q03nCk_M0

Did you know that up to 40% of patients treated surgically for common solid tumors experience recurrence? A recent poll reveals how oncologists are addressing barriers to cancer care and recurrence monitoring with MRD testing. Explore all the findings: hubs.la/Q03nCnc00

Have questions about MRD testing or ctDNA technology? Our experts will be at #ASCO25 at the Quest Diagnostics booth 11069 and ready to connect! hubs.la/Q03lj3Jk0 #OncologyCare #MRD

Heading to #ASCO25? Let’s meet! Request a 1:1 with our team to discuss how ultrasensitive MRD testing can support your practice. 📍 Booth 11069 🔗 hubs.la/Q03lhnmW0 #MRD #ctDNA #PrecisionOncology

At #ASCO25? Don’t miss the opportunity to see the science behind the innovation. Visit our poster on ctDNA analysis for improved treatment response assessment and prediction of clinical outcomes in patients with esophageal cancer. Saturday, 9-12PM hubs.la/Q03lhYlF0

As part of Quest Diagnostics, Haystack MRD™ offers end-to-end reliability from testing to results, making patient care smoother. Learn more at hubs.la/Q038gVqS0 #QuestDiagnostics #OncologyTesting

New data shows that Haystack MRD detected recurrence in patients with esophageal cancer up to 22 months earlier than imaging. Stop by booth 11069 to learn more! #ASCO25 #HaystackMRD #precisiononcology

Last chance to catch us at #ASCO25! Stop by Quest Diagnostics booth 11069 to learn how our MRD test helps clinicians detect recurrence early and with confidence. hubs.la/Q03q4jjD0 #MRDtesting #ctDNA #CancerDetection

Haystack MRD™ guides personalized therapy decisions, helping clinicians answer key questions like: ‘Is adjuvant therapy needed? Learn more at hubs.la/Q038gVqV0 #PrecisionMedicine #OncologyTesting